Now after reading the original paper I notice that the authors themselves note a possible therapeutic strategy RBBP4 works at least in part through the PKA CREB1 CPB pathway The author have previously shown that dopamine D1 D5 agonists such as 6 Br APB and SKF 38 393 that are positively coupled to adenylyl cyclase and the cAMP phosphodieserase inhibitor rolipram reduced meomory defects in aged mice